Scaling-up the Systems Analysis and Improvement Approach for prevention of mother-to-child HIV transmission in Mozambique (SAIA-SCALE): a stepped-wedge cluster randomized trial.


Journal

Implementation science : IS
ISSN: 1748-5908
Titre abrégé: Implement Sci
Pays: England
ID NLM: 101258411

Informations de publication

Date de publication:
27 04 2019
Historique:
received: 29 03 2019
accepted: 10 04 2019
entrez: 29 4 2019
pubmed: 29 4 2019
medline: 27 8 2019
Statut: epublish

Résumé

The introduction of option B+-rapid initiation of lifelong antiretroviral therapy regardless of disease status for HIV-infected pregnant and breastfeeding women-can dramatically reduce HIV transmission during pregnancy, birth, and breastfeeding. Despite significant investments to scale-up Option B+, results have been mixed, with high rates of loss to follow-up, sub-optimal viral suppression, continued pediatric HIV transmission, and HIV-associated maternal morbidity. The Systems Analysis and Improvement Approach (SAIA) cluster randomized trial demonstrated that a package of systems engineering tools improved flow through the prevention of mother-to-child HIV transmission (PMTCT) cascade. This five-step, facility-level intervention is designed to improve understanding of gaps (cascade analysis), guide identification and prioritization of low-cost workflow modifications (process mapping), and iteratively test and redesign these modifications (continuous quality improvement). This protocol describes a novel model for SAIA delivery (SAIA-SCALE) led by district nurse supervisors (rather than research nurses), and evaluation procedures, to serve as a foundation for national scale-up. The SAIA-SCALE stepped wedge trial includes three implementation waves, each 12 months in duration. Districts are the unit of assignment, with four districts randomly assigned per wave, covering all 12 districts in Manica province, Mozambique. In each district, the three highest volume health facilities will receive the SAIA-SCALE intervention (totaling 36 intervention facilities). The RE-AIM framework will guide SAIA-SCALE's evaluation. Reach describes the proportion of clinics and population in Manica province reached, and sub-groups not reached. Effectiveness assesses impact on PMTCT process measures and patient-level outcomes. Adoption describes the proportion of districts/clinics adopting SAIA-SCALE, and determinants of adoption using the Organizational Readiness for Implementing Change (ORIC) tool. Implementation will identify SAIA-SCALE core elements and determinants of successful implementation using the Consolidated Framework for Implementation Research (CFIR). Maintenance describes the proportion of districts sustaining the intervention. We will also estimate the budget and program impact from the payer perspective for national scale-up. SAIA packages user-friendly systems engineering tools to guide decision-making by frontline health workers, and to identify low-cost, contextually appropriate PMTCT improvement strategies. By integrating SAIA delivery into routine management structures, this pragmatic trial is designed to test a model for national intervention scale-up. ClinicalTrials.gov NCT03425136 (registered 02/06/2018).

Sections du résumé

BACKGROUND
The introduction of option B+-rapid initiation of lifelong antiretroviral therapy regardless of disease status for HIV-infected pregnant and breastfeeding women-can dramatically reduce HIV transmission during pregnancy, birth, and breastfeeding. Despite significant investments to scale-up Option B+, results have been mixed, with high rates of loss to follow-up, sub-optimal viral suppression, continued pediatric HIV transmission, and HIV-associated maternal morbidity. The Systems Analysis and Improvement Approach (SAIA) cluster randomized trial demonstrated that a package of systems engineering tools improved flow through the prevention of mother-to-child HIV transmission (PMTCT) cascade. This five-step, facility-level intervention is designed to improve understanding of gaps (cascade analysis), guide identification and prioritization of low-cost workflow modifications (process mapping), and iteratively test and redesign these modifications (continuous quality improvement). This protocol describes a novel model for SAIA delivery (SAIA-SCALE) led by district nurse supervisors (rather than research nurses), and evaluation procedures, to serve as a foundation for national scale-up.
METHODS
The SAIA-SCALE stepped wedge trial includes three implementation waves, each 12 months in duration. Districts are the unit of assignment, with four districts randomly assigned per wave, covering all 12 districts in Manica province, Mozambique. In each district, the three highest volume health facilities will receive the SAIA-SCALE intervention (totaling 36 intervention facilities). The RE-AIM framework will guide SAIA-SCALE's evaluation. Reach describes the proportion of clinics and population in Manica province reached, and sub-groups not reached. Effectiveness assesses impact on PMTCT process measures and patient-level outcomes. Adoption describes the proportion of districts/clinics adopting SAIA-SCALE, and determinants of adoption using the Organizational Readiness for Implementing Change (ORIC) tool. Implementation will identify SAIA-SCALE core elements and determinants of successful implementation using the Consolidated Framework for Implementation Research (CFIR). Maintenance describes the proportion of districts sustaining the intervention. We will also estimate the budget and program impact from the payer perspective for national scale-up.
DISCUSSION
SAIA packages user-friendly systems engineering tools to guide decision-making by frontline health workers, and to identify low-cost, contextually appropriate PMTCT improvement strategies. By integrating SAIA delivery into routine management structures, this pragmatic trial is designed to test a model for national intervention scale-up.
TRIAL REGISTRATION
ClinicalTrials.gov NCT03425136 (registered 02/06/2018).

Identifiants

pubmed: 31029171
doi: 10.1186/s13012-019-0889-z
pii: 10.1186/s13012-019-0889-z
pmc: PMC6487047
doi:

Banques de données

ClinicalTrials.gov
['NCT03425136']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural

Langues

eng

Pagination

41

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI027757
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH113435
Pays : United States

Références

J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):427-438
pubmed: 29287029
Arch Intern Med. 2001 Oct 22;161(19):2357-65
pubmed: 11606152
BMC Res Notes. 2014 Oct 21;7:743
pubmed: 25335783
Am J Trop Med Hyg. 2009 Jun;80(6):971-9
pubmed: 19478260
J Acquir Immune Defic Syndr. 2014 Nov 1;67 Suppl 2:S125-31
pubmed: 25310118
Am J Obstet Gynecol. 2007 Sep;197(3 Suppl):S83-9
pubmed: 17825654
BMC Health Serv Res. 2013;13 Suppl 2:S4
pubmed: 23819552
J Acquir Immune Defic Syndr. 2016 Aug 1;72 Suppl 2:S174-80
pubmed: 27355506
Implement Sci. 2014 Jan 10;9:7
pubmed: 24410955
J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):e68-76
pubmed: 27082507
J Int AIDS Soc. 2016 May 11;19(1):20864
pubmed: 27174911
Psychiatr Serv. 2016 Jun 1;67(6):588-90
pubmed: 26828400
Ann Intern Med. 1997 Jun 15;126(12):946-54
pubmed: 9182471
Trop Med Int Health. 2016 Aug;21(8):1003-1012
pubmed: 27208807
BMC Public Health. 2009 Nov 05;9:406
pubmed: 19891775
Ann Intern Med. 2011 Mar 15;154(6):384-90
pubmed: 21403074
PLoS Med. 2006 May;3(5):e138
pubmed: 16573364
Lancet. 2012 Dec 15;380(9859):2197-223
pubmed: 23245608
J Acquir Immune Defic Syndr. 2016 Aug 1;72 Suppl 2:S108-16
pubmed: 27355497
Glob Health Action. 2016 Aug 30;9:31980
pubmed: 27580822
J Int AIDS Soc. 2011 Dec 28;14:61
pubmed: 22204313
Implement Sci. 2014 May 08;9:55
pubmed: 24885976
BMC Public Health. 2009 Nov 18;9 Suppl 1:S5
pubmed: 19922689
Am J Public Health. 1999 Sep;89(9):1322-7
pubmed: 10474547
Curr HIV/AIDS Rep. 2018 Dec;15(6):414-422
pubmed: 30259258
JAMA. 2007 Jun 6;297(21):2349-50
pubmed: 17551128
BMC Health Serv Res. 2010 Jan 07;10:7
pubmed: 20056005
JAMA. 2007 Oct 24;298(16):1937-9
pubmed: 17954547
Trop Med Int Health. 2014 Jul;19(7):791-801
pubmed: 24724617

Auteurs

Kenneth Sherr (K)

Department of Global Health, University of Washington Schools of Medicine and Public Health, 1705 NE Pacific St, Seattle, WA, 98195, USA. ksherr@uw.edu.
Health Alliance International (HAI), 1107 NE 45th St, Suite 350, Seattle, WA, 98105, USA. ksherr@uw.edu.

Kristjana Ásbjörnsdóttir (K)

Department of Epidemiology, University of Washington School of Public Health, 1705 NE Pacific St, Seattle, WA, 98195, USA.

Jonny Crocker (J)

Department of Global Health, University of Washington Schools of Medicine and Public Health, 1705 NE Pacific St, Seattle, WA, 98195, USA.

Joana Coutinho (J)

Health Alliance International (HAI), 1107 NE 45th St, Suite 350, Seattle, WA, 98105, USA.

Maria de Fatima Cuembelo (M)

Community Health Department, School of Medicine, Eduardo Mondlane University, Avenida Salvador Allende, 702, Maputo, Mozambique.

Esperança Tavede (E)

Manica Provincial Health Department, Ave 25 de Setembro, Chimoio, Mozambique.

Nélia Manaca (N)

Health Alliance International (HAI), 1107 NE 45th St, Suite 350, Seattle, WA, 98105, USA.

Keshet Ronen (K)

Department of Global Health, University of Washington Schools of Medicine and Public Health, 1705 NE Pacific St, Seattle, WA, 98195, USA.

Felipe Murgorgo (F)

Manica Provincial Health Department, Ave 25 de Setembro, Chimoio, Mozambique.

Ruanne Barnabas (R)

Department of Global Health, University of Washington Schools of Medicine and Public Health, 1705 NE Pacific St, Seattle, WA, 98195, USA.

Grace John-Stewart (G)

Department of Global Health, University of Washington Schools of Medicine and Public Health, 1705 NE Pacific St, Seattle, WA, 98195, USA.

Sarah Holte (S)

Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA, 98109, USA.

Bryan J Weiner (BJ)

Department of Global Health, University of Washington Schools of Medicine and Public Health, 1705 NE Pacific St, Seattle, WA, 98195, USA.

James Pfeiffer (J)

Department of Global Health, University of Washington Schools of Medicine and Public Health, 1705 NE Pacific St, Seattle, WA, 98195, USA.
Health Alliance International (HAI), 1107 NE 45th St, Suite 350, Seattle, WA, 98105, USA.

Sarah Gimbel (S)

Department of Global Health, University of Washington Schools of Medicine and Public Health, 1705 NE Pacific St, Seattle, WA, 98195, USA.
Health Alliance International (HAI), 1107 NE 45th St, Suite 350, Seattle, WA, 98105, USA.
Department of Family and Child Nursing, University of Washington School of Nursing, 1959 NE Pacific St, Seattle, WA, 98195, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH